[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 18 of about 18
1. Tonyali O, Coskun U, Yildiz R, Karakan T, Demirci U, Akyurek N, Benekli M, Buyukberber S: Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. Med Oncol; 2010 Sep;27(3):768-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors.
  • Imatinib mesylate is a drug that has been approved for treatment of chronic myeloid leukemia, Philadelphia-positive acute lymphoblastic leukemia, and advanced gastrointestinal stromal tumors.
  • We report a 53-year-old woman with advanced gastrointestinal stromal tumors who developed hepatotoxicity while receiving imatinib and subsequently acute liver failure.
  • Biopsy showed sinusoidal congestion, necrosis of hepatocytes, inflammation, and hepatocyte drop out around the hepatic venule consistent with drug toxicity.
  • In cases of imatinib-induced acute hepatitis, the administration of prednisolone may be useful in the resolution of the acute episode and allow the reintroduction of a drug without risking recurrence of hepatitis.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Chemical and Drug Induced Liver Injury / etiology. Gastrointestinal Stromal Tumors / drug therapy. Intestinal Neoplasms / drug therapy. Liver Failure / chemically induced. Piperazines / adverse effects. Protein Kinase Inhibitors / adverse effects. Pyrimidines / adverse effects
  • [MeSH-minor] Acute Disease. Anti-Inflammatory Agents / therapeutic use. Benzamides. Female. Humans. Imatinib Mesylate. Indoles / therapeutic use. Liver / pathology. Middle Aged. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Prednisolone / therapeutic use. Pyrroles / therapeutic use

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Nov;18(11):1235-7 [17033447.001]
  • [Cites] J Clin Gastroenterol. 2005 Jan;39(1):75-7 [15599217.001]
  • [Cites] Singapore Med J. 2008 Mar;49(3):e86-9 [18362995.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2349-51 [15512829.001]
  • [Cites] Acta Haematol. 2007;118(4):205-8 [18030002.001]
  • [Cites] Leukemia. 2002 Oct;16(10 ):2160-1 [12357373.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Hematology. 2007 Feb;12(1):49-53 [17364993.001]
  • [Cites] Leuk Lymphoma. 2006 Jan;47(1):155-7 [16321842.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1928-37 [11877262.001]
  • [Cites] World J Gastroenterol. 2007 Dec 28;13(48):6608-111 [18161937.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Jul;18(7):785-7 [16772838.001]
  • [Cites] Gastroenterol Hepatol. 2007 Nov;30(9):525-30 [17980129.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3455-6 [14568907.001]
  • [Cites] Leukemia. 2003 May;17 (5):978-9 [12750713.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):935-42 [12006504.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Haematologica. 2006 Jun;91(6 Suppl):ECR27 [16785130.001]
  • [Cites] Dig Dis Sci. 2007 Feb;52(2):598-601 [17219077.001]
  • [Cites] Am J Hematol. 2006 Mar;81(3):189-92 [16493605.001]
  • (PMID = 19662540.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Indoles; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Pyrroles; 8A1O1M485B / Imatinib Mesylate; 9PHQ9Y1OLM / Prednisolone; V99T50803M / sunitinib
  •  go-up   go-down


2. Kim SJ, Park TS, Lee ST, Song J, Suh B, Kim SH, Jang SJ, Lee CH, Choi JR: Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme. Ann Clin Lab Sci; 2009;39(4):392-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.
  • Therapy-related myelodysplastic syndrome and acute leukemia after treatment with temozolomide have rarely been described in the literature.
  • The cases included anaplastic astrocytoma (4 cases), anaplastic oligodendroglioma (2 cases), low grade astrocytoma (2 cases), low grade oligodendroglioma (1 case), and one case of secondary Philadelphia-positive acute lymphoblastic leukemia in a patient with glioblastoma multiforme.
  • Here we report a novel case of therapy-related myelodysplastic syndrome/acute myeloid leukemia associated with der(1;7)(q10;p10) in a glioblastoma multiforme patient treated with temozolomide.
  • In past reports, karyotypes in cases of therapy-related myelodysplastic syndrome/acute myeloid leukemia mostly demonstrated abnormalities in chromosomes 5 and 7.
  • However, we report a case of temozolomide-related myelodysplastic syndrome/acute myeloid leukemia with der(1;7)(q10;p10), possibly the first reported case, to the authors' knowledge.
  • [MeSH-major] Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Leukemia, Myeloid, Acute / chemically induced. Myelodysplastic Syndromes / chemically induced
  • [MeSH-minor] Adult. Aged. Biopsy. Bone Marrow Cells / pathology. Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Disease Progression. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Magnetic Resonance Imaging. Male. Middle Aged. Skin / pathology


3. Iacobucci I, Lonetti A, Messa F, Cilloni D, Arruga F, Ottaviani E, Paolini S, Papayannidis C, Piccaluga PP, Giannoulia P, Soverini S, Amabile M, Poerio A, Saglio G, Pane F, Berton G, Baruzzi A, Vitale A, Chiaretti S, Perini G, Foà R, Baccarani M, Martinelli G: Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood; 2008 Nov 1;112(9):3847-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.
  • We sought to determine whether molecular abnormalities involving the IKZF1 gene were associated with resistance to tyrosine kinase inhibitors (TKIs) in Ph+ acute lymphoblastic leukemia (ALL) patients.
  • There was a strong correlation between nonfunctional Ikaros isoforms and BCR-ABL transcript level.
  • Furthermore, patient-derived leukemia cells expressed oncogenic Ikaros isoforms before TKI treatment, but not during response to TKIs, and predominantly at the time of relapse.
  • [MeSH-major] Ikaros Transcription Factor / genetics. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Alternative Splicing. Antineoplastic Agents / pharmacokinetics. Base Sequence. Benzamides. Cell Line, Tumor. DNA Primers / genetics. DNA, Neoplasm / genetics. Dasatinib. Drug Resistance, Neoplasm / genetics. Genes, abl. Humans. Imatinib Mesylate. Middle Aged. Mutation. Piperazines / pharmacology. Protein Isoforms / genetics. Protein Kinase Inhibitors / pharmacology. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / pharmacology. Thiazoles / pharmacology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Blood. 2010 Sep 23;116(12):2196
  • (PMID = 18650450.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / IKZF1 protein, human; 0 / Piperazines; 0 / Protein Isoforms; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 148971-36-2 / Ikaros Transcription Factor; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; RBZ1571X5H / Dasatinib
  •  go-up   go-down


Advertisement
4. Tiribelli M, Sperotto A, Candoni A, Simeone E, Buttignol S, Fanin R: Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk Res; 2009 Jan;33(1):174-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib.
  • Prognosis of patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation (SCT) is dismal.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphocyte Transfusion. Philadelphia Chromosome. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / therapeutic use. Stem Cell Transplantation
  • [MeSH-minor] Benzamides. Drug Resistance, Neoplasm. Humans. Imatinib Mesylate. Male. Middle Aged. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18471874.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


5. Lee S, Kim SH, Choi SM, Lee DG, Kim SY, Lee JW, Min WS, Shin WS, Kim CC: Cytomegalovirus ventriculoencephalitis after unrelated double cord blood stem cell transplantation with an alemtuzumab-containing preparative regimen for Philadelphia-positive acute lymphoblastic leukemia. J Korean Med Sci; 2010 Apr;25(4):630-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomegalovirus ventriculoencephalitis after unrelated double cord blood stem cell transplantation with an alemtuzumab-containing preparative regimen for Philadelphia-positive acute lymphoblastic leukemia.
  • Despite the prophylaxis and preemptive strategies using potent antiviral agents, cytomegalovirus (CMV) remains a major infectious cause of morbidity and mortality in allogeneic stem cell transplantation (SCT) recipients.
  • Delayed immune reconstitution after SCT, such as cord blood and T-cell depleted SCT with the use of alemtuzumab, has been associated with an increased frequency of CMV disease as well as CMV reactivation.
  • We report a case of CMV ventriculoencephalitis after unrelated double cord blood SCT with an alemtuzumab-containing preparative regimen for Philadelphia-positive acute lymphoblastic leukemia.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Cord Blood Stem Cell Transplantation / adverse effects. Cytomegalovirus Infections / drug therapy. Cytomegalovirus Infections / etiology. Encephalitis. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Cytomegalovirus / drug effects. Fatal Outcome. Humans. Male. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • MedlinePlus Health Information. consumer health - Encephalitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2000 Mar 31;14(5):517-24 [10780714.001]
  • [Cites] Clin Infect Dis. 2006 Jul 1;43(1):16-24 [16758413.001]
  • [Cites] Clin Infect Dis. 2001 Nov 1;33(9):e105-8 [11577375.001]
  • [Cites] Clin Infect Dis. 2002 May 15;34(10):1337-41 [11981729.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4357-63 [12036862.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3843-4 [12411329.001]
  • [Cites] Transpl Infect Dis. 2002 Dec;4(4):201-6 [12535263.001]
  • [Cites] Br J Haematol. 2003 Apr;121(2):304-11 [12694253.001]
  • [Cites] Bone Marrow Transplant. 2004 Jan;33(2):243-5 [14716290.001]
  • [Cites] Clin Pharmacol Ther. 1986 Sep;40(3):281-6 [3017630.001]
  • [Cites] N Engl J Med. 1990 Sep 20;323(12):833-4 [1697401.001]
  • [Cites] Drugs. 1994 Aug;48(2):199-226 [7527325.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1290-2 [16154862.001]
  • [Cites] Clin Infect Dis. 2006 Feb 15;42(4):e26-9 [16421783.001]
  • [Cites] Bone Marrow Transplant. 2000 Aug;26(3):251-5 [10967562.001]
  • (PMID = 20358010.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  • [Other-IDs] NLM/ PMC2844610
  • [Keywords] NOTNLM ; Alemtuzumab / Cord Blood Stem Cell Transplantation / Cytomegalovirus / Encephalitis / Leukemia
  •  go-up   go-down


6. Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, Bornhäuser M, Reichle A, Perz J, Haas R, Ganser A, Schmid M, Kanz L, Lenz G, Kaufmann M, Binckebanck A, Brück P, Reutzel R, Gschaidmeier H, Schwartz S, Hoelzer D, Ottmann OG: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood; 2006 Sep 1;108(5):1469-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
  • The best strategy for incorporating imatinib in front-line treatment of Ph+ acute lymphoblastic leukemia (ALL) has not been established.
  • Coadministration of imatinib and induction cycle 2 (INDII) resulted in a complete remission (CR) rate of 95% and polymerase chain reaction (PCR) negativity for BCR-ABL in 52% of patients, compared with 19% in patients in the alternating treatment cohort (P = .01).
  • In the concurrent cohort, grades III and IV cytopenias and transient hepatotoxicity necessitated interruption of induction in 87% and 53% of patients, respectively; however, duration of induction was not prolonged when compared with patients receiving chemotherapy alone.
  • In each cohort, 77% of patients underwent allogeneic stem cell transplantation (SCT) in first CR (CR1).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Benzamides. Bone Marrow / pathology. Drug Administration Schedule. Drug Therapy, Combination. Female. Fusion Proteins, bcr-abl / deficiency. Fusion Proteins, bcr-abl / genetics. Humans. Imatinib Mesylate. Male. Middle Aged. Polymerase Chain Reaction. Probability. Remission Induction. Survival Analysis. Transcription, Genetic. Treatment Outcome


7. Scheuring UJ, Pfeifer H, Wassmann B, Brück P, Gehrke B, Petershofen EK, Gschaidmeier H, Hoelzer D, Ottmann OG: Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment. Leukemia; 2003 Sep;17(9):1700-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
  • Patients with refractory or relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) rarely have prolonged responses to salvage therapy, including imatinib, resulting in a short opportunity for potentially curative stem cell transplantation.
  • To identify minimal residual disease (MRD) parameters predictive of imminent relapse, we quantitated Bcr-Abl expression by real-time PCR in peripheral blood (PB) and bone marrow (BM) of 24 Ph+ALL patients after achieving a complete response and MRD minimum.
  • The ratio of Bcr-Abl and glyceraldehyde-3-phosphate dehydrogenase copies, magnitude of increase and velocity of increase were evaluated regarding subsequent time intervals to relapse, death or censoring.
  • High Bcr-Abl levels >/=5 x 10(-4) in PB (n=23) and >/=10(-4) in BM (n=18) were significantly associated with short time periods to relapse.
  • Bcr-Abl increases >2 logarithmic units (log) in PB, but not in BM preceded short-term relapse.
  • The velocity of Bcr-Abl increases predicted response duration in PB (cutoff: 1.25 log/30 days) and BM (0.6).
  • Bcr-Abl level and velocity of increase in BM as well as magnitude of increase in PB correlated with remaining periods of survival and predicted relapse within 2 months in nine of 10, 10 of 11 and four of four patients, respectively.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasm, Residual / diagnosis. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / therapeutic use. RNA, Messenger / analysis
  • [MeSH-minor] Benzamides. Bone Marrow / metabolism. Bone Marrow / pathology. Fusion Proteins, bcr-abl / genetics. Fusion Proteins, bcr-abl / metabolism. Glyceraldehyde-3-Phosphate Dehydrogenases / metabolism. Humans. Imatinib Mesylate. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / metabolism. Protein-Tyrosine Kinases / antagonists & inhibitors. RNA, Neoplasm / genetics. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2003 Sep;17(9):1722 [12970770.001]
  • (PMID = 12970767.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 8A1O1M485B / Imatinib Mesylate; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


8. Verstovsek S, Golemovic M, Kantarjian H, Manshouri T, Estrov Z, Manley P, Sun T, Arlinghaus RB, Alland L, Dugan M, Cortes J, Giles F, Beran M: AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer; 2005 Sep 15;104(6):1230-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
  • BACKGROUND: Previous studies have shown that patients with Bcr-Abl-positive acute lymphoblastic leukemia (ALL) either have primary disease that is refractory to imatinib mesylate or develop disease recurrence after an initial response.
  • METHODS: The authors investigated the effects of a newly designed Bcr-Abl inhibitor, AMN107, by comparing its in vitro inhibitory potency on p190 Bcr-Abl ALL cell lines with that of imatinib.
  • RESULTS: In two Philadelphia (Ph)-positive ALL cell lines, AMN107 was found to be 30-40 times more potent than imatinib in inhibiting cellular proliferation.
  • AMN107 was also more effective than imatinib in inhibiting phosphorylation of p190 Bcr-Abl tyrosine kinase in cell lines and primary ALL cells.
  • The inhibition of cellular proliferation was associated with the induction of apoptosis in only one of the cell lines.
  • No activity was observed in cell lines lacking the BCR-ABL genotype.
  • CONCLUSIONS: The results of the current study suggest the superior potency of AMN107 compared with imatinib in Ph-positive ALL and support clinical trials of AMN107 in patients with Ph-positive ALL.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Fusion Proteins, bcr-abl / antagonists & inhibitors. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Benzamides. Caspase 3. Caspases / metabolism. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Humans. Imatinib Mesylate. Phosphorylation. Piperazines / pharmacology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16078266.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


9. Pane F, Cimino G, Izzo B, Camera A, Vitale A, Quintarelli C, Picardi M, Specchia G, Mancini M, Cuneo A, Mecucci C, Martinelli G, Saglio G, Rotoli B, Mandelli F, Salvatore F, Foà R, GIMEMA group: Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia; 2005 Apr;19(4):628-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
  • Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has a dismal prognosis.
  • We prospectively evaluated minimal residual disease (MRD) by measuring BCR/ ABL levels with a quantitative real-time PCR procedure after induction and after consolidation in 45 adults with Ph+ ALL who obtained complete hematological remission after a high-dose daunorubicin induction schedule.
  • At diagnosis, the mean BCR-ABL/GUS ratio was 1.55 +/- 1.78.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fusion Proteins, bcr-abl / genetics. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Asparaginase / therapeutic use. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm, Residual / drug therapy. Neoplasm, Residual / genetics. Neoplasm, Residual / mortality. Predictive Value of Tests. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744351.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


10. Nishioka C, Ikezoe T, Yang J, Yokoyama A: Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene. Leukemia; 2010 Sep;24(9):1631-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene.
  • Imatinib induces complete molecular response in patients with chronic myeloid leukemia (CML) and chronic eosinophilic leukemia (CEL).
  • However, development of resistance to imatinib has emerged as an important clinical problem for molecular-targeted therapy in CML and CEL.
  • Notably, hypermethylation of the promoter region of the PTEN gene in association with the downregulation of this gene's transcripts was identified in imatinib-resistant leukemia cells isolated from individuals with CEL, CML and Philadelphia-positive acute lymphoblastic leukemia.
  • In addition, anti-epigenetic agents restored PTEN expression, resulting in the sensitization of EOL-1R cells to imatinib.
  • Taken together, epigenetic silence of PTEN is one of the mechanisms that cause drug resistance in individuals with leukemia after exposure to imatinib.
  • Anti-epigenetic agents may be useful for overcoming drug resistance in such a case.
  • [MeSH-major] Epigenesis, Genetic. Extracellular Signal-Regulated MAP Kinases / metabolism. Gene Silencing. Hypereosinophilic Syndrome / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. PTEN Phosphohydrolase / genetics. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins c-akt / metabolism. STAT5 Transcription Factor / metabolism. Signal Transduction
  • [MeSH-minor] Base Sequence. Blotting, Western. Cell Cycle / drug effects. Cell Line, Tumor. Chromatin Immunoprecipitation. DNA Primers. Enzyme Activation. Flow Cytometry. Humans. Reverse Transcriptase Polymerase Chain Reaction


11. Rea D, Legros L, Raffoux E, Thomas X, Turlure P, Maury S, Dupriez B, Pigneux A, Choufi B, Reman O, Stéphane D, Royer B, Vigier M, Ojeda-Uribe M, Recher C, Dombret H, Huguet F, Rousselot P, Intergroupe Français des Leucémies Myéloïdes Chronique, Group for Research in Adult Acute Lymphoblastic Leukemia: High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia; 2006 Mar;20(3):400-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
  • Imatinib combined with high-dose chemotherapy is now becoming the gold standard for treatment of Philadelphia chromosome-positive acute leukemias.
  • Thirty-one patients (18 relapsing or refractory Ph+ acute lymphoblastic leukemias and 13 lymphoid blast crisis chronic myelogenous leukemias) were enrolled.
  • The median bcr-abl/abl ratio after the induction course was 0.1%.
  • Nine out of 19 patients under 55 years received allogenic stem cell transplantation after a median time of 78 days post-CR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blast Crisis / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Benzamides. Dexamethasone / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Humans. Imatinib Mesylate. Pilot Projects. Piperazines / administration & dosage. Pyrimidines / administration & dosage. Vincristine / administration & dosage


12. Ramakers-van Woerden NL, Pieters R, Hoelzer D, Slater RM, den Boer ML, Loonen AH, Harbott J, Janka-Schaub GE, Ludwig WD, Ossenkoppele GJ, van Wering ER, Veerman AJ, Dutch and German Leukemia Study Groups: In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups. Med Pediatr Oncol; 2002 Jun;38(6):379-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups.
  • BACKGROUND: The t(9;22)(q34;q11) translocation leading to the Philadelphia (Ph) chromosome resulting in BCR-ABL gene fusion is associated with a poor prognosis in acute lymphoblastic leukemia (ALL).
  • PROCEDURE: We studied the relation between t(9;22), determined by karyotype, fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR), and in vitro drug resistance, measured by the MTT assay, in precursor B-cell ALL at diagnosis.
  • The findings in twenty-one Ph-positive (Ph+) childhood common/precursorB (c/preB) cases were compared with 254 Ph-negative (Ph-) ALL cases.
  • Moreover, LC(50) values did not differ significantly between Ph+ and Ph- samples for prednisolone, dexamethasone, L-asparaginase, vincristine, anthracyclines, thiopurines, epipodophyllotoxins, and 4H00-ifosfamide, even after matching for important prognostic features (age, white blood cell count (WBC), and immunophenotype).
  • Adult Ph+ (n = 12) ALL was more resistant to prednisolone (> 270-fold, P = 0.030), and displayed an overall tendency to resistance when compared to matched cases of Ph- (n = 15) adult precursor B-cell ALL.
  • CONCLUSIONS: Both childhood and adult Ph+ precursor B-cell ALL samples display a heterogeneous in vitro resistance profile, with relatively sensitive and resistant cases.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Child. Drug Screening Assays, Antitumor. Humans. Immunophenotyping. In Vitro Techniques. Leukocyte Count. Multidrug Resistance-Associated Proteins / analysis. Multidrug Resistance-Associated Proteins / genetics. Neoplasm Proteins / analysis. Neoplasm Proteins / genetics. P-Glycoprotein / analysis. P-Glycoprotein / genetics. Philadelphia Chromosome. Prednisolone / therapeutic use. Prognosis. Vault Ribonucleoprotein Particles / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 11984797.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 0 / multidrug resistance-associated protein 1; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


13. Czyz A, Lewandowski K, Kroll R, Komarnicki M: Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion. Med Oncol; 2010 Dec;27(4):1123-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
  • Presence of the Philadelphia chromosome in acute lymphoblastic leukemia is the single most adverse prognostic marker associated with high risk of disease relapse and poor prognosis.
  • Allogeneic haematopoietic stem cell transplantation is considered as the only curative option in adults with Philadelphia-positive acute lymphoblastic leukemia, but relapse remains the main cause of treatment failure.
  • Incorporation of tyrosine kinase inhibitors into transplantation strategy in patients with Philadelphia-positive acute lymphoblastic leukemia may improve prognosis of the disease.
  • Imatinib combined with conventional chemotherapy and used in conjunction with allogeneic hematopoietic stem cell transplantation has improved long-term survival rates.
  • The more potent multikinase inhibitor dasatinib has shown enhanced activity in Philadelphia-positive acute lymphoblastic leukemia and has been approved for the treatment of adults with resistance or intolerance to prior imatinib therapy.
  • Here, we present a case of Philadelphia-positive acute lymphoblastic leukemia primary resistant to imatinib combined with chemotherapy.
  • Subsequently, the patient underwent allogeneic hematopoietic stem cell transplantation as a salvage therapy.
  • [MeSH-major] Drug Resistance, Neoplasm. Hematopoietic Stem Cell Transplantation. Piperazines / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / adverse effects. Pyrimidines / therapeutic use. Salvage Therapy. Thiazoles / therapeutic use
  • [MeSH-minor] Benzamides. Dasatinib. Female. Humans. Imatinib Mesylate. Middle Aged. Neoplasm, Residual / drug therapy. Neoplasm, Residual / pathology. Prognosis. Protein Kinase Inhibitors / therapeutic use. Remission Induction. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2009 Feb 1;115(3):561-70 [19117346.001]
  • [Cites] Blood. 2005 Jul 15;106(2):458-63 [15817679.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Mar;9(3):206-12 [12652472.001]
  • [Cites] Leukemia. 1997 Feb;11(2):294-8 [9009095.001]
  • [Cites] Ann Hematol. 2006 Oct;85(10):717-22 [16832677.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2791-3 [17119111.001]
  • [Cites] Leukemia. 2005 Apr;19(4):628-35 [15744351.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2309-15 [17496201.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Br J Haematol. 2008 Jun;142(2):227-37 [18492099.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2602-9 [9116308.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2357-66 [12239143.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Bone Marrow Transplant. 2009 Apr;43(7):579-81 [18978822.001]
  • [Cites] Curr Opin Oncol. 2009 Jun;21 Suppl 1:S43-6 [19561414.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1408-13 [17062730.001]
  • [Cites] Leukemia. 1999 Mar;13(3):419-27 [10086733.001]
  • (PMID = 19885746.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; RBZ1571X5H / Dasatinib
  •  go-up   go-down


14. Fujimaki K, Tanaka M, Takasaki H, Hyo R, Kawano T, Sakai R, Fujita H, Fujisawa S, Kanamori H, Maruta A, Ishigatsubo Y: Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients aged 50 years and over. Intern Med; 2008;47(5):379-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients aged 50 years and over.
  • OBJECTIVE: To reduce the relapse rate for hematological malignancies after allogeneic hematopoietic stem cell transplantation, we employed a myeloablative regimen comprising thiotepa 400 mg/m(2), cyclophosphamide 3,600 mg/m(2) and total body irradiation 10 Gy.
  • MATERIALS AND METHODS: Subjects comprised 17 patients (median age, 53 years; range, 50-56 years) with hematological malignancies who received allogeneic hematopoietic stem cell transplantation from HLA-identical related (n=6), HLA-mismatched family (n=2) or unrelated donors (n=9).
  • Prophylaxis of acute graft-versus-host disease (GVHD) consisted of short-term methotrexate and cyclosporine (n=4) or short-term methotrexate and tacrolimus (n=13).
  • RESULTS: No grade IV regimen-related toxicities as determined by Bearman's criteria were encountered.
  • Acute grade II-IV GVHD developed in 7 patients, with chronic GVHD in 11 patients.
  • Only 1 patient with Philadelphia-positive acute lymphoblastic leukemia experienced relapse.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Cyclophosphamide / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Thiotepa / administration & dosage. Transplantation Conditioning / methods. Whole-Body Irradiation
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Dosage Calculations. Female. Humans. Male. Middle Aged. Pilot Projects. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18310967.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa
  •  go-up   go-down


15. Ottmann OG, Hoelzer D: The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities. Hematol J; 2002;3(1):2-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11960387.001).
  • [ISSN] 1466-4860
  • [Journal-full-title] The hematology journal : the official journal of the European Haematology Association
  • [ISO-abbreviation] Hematol. J.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 29
  •  go-up   go-down


16. Ferrao PT, Frost MJ, Siah SP, Ashman LK: Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood; 2003 Dec 15;102(13):4499-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Elevated expression of multidrug efflux pumps such as P-glycoprotein (Pgp) have been associated with resistance to cytotoxic drugs used in the treatment of leukemias and other cancers.
  • Imatinib mesylate (STI-571 or Gleevec) is a potent inhibitor of the BCR/ABL and c-KIT tyrosine kinases.
  • It has displayed considerable efficacy in treatment of patients with Philadelphia-positive acute lymphoblastic leukemia and chronic myelogenous leukemia and those with gastrointestinal stromal tumors (GISTs).
  • However, recently imatinib-resistant relapse has emerged as a significant problem.
  • The imatinib-sensitive human leukemic cell line K562, which is dependent on the activity of BCR/ABL for survival and growth, provides a convenient system for evaluating modulation of drug activity.
  • By expressing Pgp at high levels in these cells, we have demonstrated that this pump provides minimal protection against cell growth inhibition and apoptosis induced by imatinib.
  • In contrast, overexpression of Bcl-xL, which blocks apoptosis, resulted in partial protection against the drug.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Resistance, Neoplasm. Enzyme Inhibitors / pharmacology. Fusion Proteins, bcr-abl / antagonists & inhibitors. K562 Cells / drug effects. Neoplasm Proteins / physiology. P-Glycoprotein / physiology. Piperazines / pharmacology. Proto-Oncogene Proteins c-bcl-2 / physiology. Pyrimidines / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Benzamides. Biological Transport. Daunorubicin / pharmacology. Gene Expression Regulation, Leukemic. Humans. Imatinib Mesylate. Recombinant Fusion Proteins / physiology. Transduction, Genetic. bcl-X Protein

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12881321.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / Benzamides; 0 / Enzyme Inhibitors; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / Piperazines; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrimidines; 0 / Recombinant Fusion Proteins; 0 / bcl-X Protein; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


17. IMAHASHI N, TOKUNAGA M, NISHIWAKI S, YANAGISAWA M, OZAWA Y, MIYAMURA K: Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation. Rinsho Ketsueki; 2009 Nov;50(11):1612-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation.
  • The prognosis of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+)ALL) relapsing after allogeneic hematopoietic stem cell transplantation is dismal.
  • Our case suggests that by continuing imatinib after the induction of molecular remission by imatinib-combined chemotherapy, the antileukemic activity of imatinib could achieve durable remission in combination with the graft-versus-leukemia effect.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Hematopoietic Stem Cell Transplantation. Neoplasm Recurrence, Local. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / administration & dosage
  • [MeSH-minor] Benzamides. Disease-Free Survival. Drug Administration Schedule. Female. Graft vs Leukemia Effect. Humans. Imatinib Mesylate. Middle Aged. Remission Induction. Transplantation, Homologous. Treatment Outcome


18. Takashima S, Numata A, Miyamoto T, Shirakawa T, Kinoshita R, Kato K, Takenaka K, Harada N, Nagafuji K, Taniguchi S, Harada M: [Acute lymphoblastic leukemia presenting with calcineurin-inhibitor induced pain syndrome after a second allogeneic bone marrow transplantation]. Rinsho Ketsueki; 2006 Oct;47(10):1372-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemia presenting with calcineurin-inhibitor induced pain syndrome after a second allogeneic bone marrow transplantation].
  • A 42-year-old woman was referred to us for the treatment of relapsed Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), which had been maintained in complete remission for seven years after an allogeneic bone marrow transplantation (allo-BMT) from an unrelated donor.
  • The pain was gradually relieved after discontinuation of TAC and administration of several analgesic drugs.
  • CIPS is rarely seen following allogeneic stem cell transplantation (allo-SCT); only three cases have been so far reported to our knowledge.
  • [MeSH-major] Bone Marrow Transplantation. Calcineurin / adverse effects. Calcineurin Inhibitors. Complex Regional Pain Syndromes / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Female. Hematopoietic Stem Cell Transplantation. Humans. Transplantation Conditioning






Advertisement